P D Lyden1, G T Lau. 1. Department of Neurosciences, UCSD School of Medicine, La Jolla 92093-0608.
Abstract
BACKGROUND: To judge the efficacy of new, putative stroke therapies, we need a method to measure neurological deficit accurately in groups of patients before and after treatment. No single measurement technique has yet proven to be universally acceptable, but one approach is the use of rating instruments that summarize the neurological deficit found on clinical examination. Currently, stroke assessment scales may be based on the examination of physical deficits, an inventory of activities of daily living, or a global evaluation of functional outcome. SUMMARY OF REVIEW: Scientific methods for authenticating stroke scales are available in the psychometric and statistical literature. We review currently available stroke scales for their validity and reliability and propose investigations needed to refine further the standardized measurement of neurological deficit following stroke. CONCLUSIONS: We suggest that clinical stroke trials include a physical deficit scale and a global rating during the acute phase and that an activities of daily living scale be added at later points in recovery.
BACKGROUND: To judge the efficacy of new, putative stroke therapies, we need a method to measure neurological deficit accurately in groups of patients before and after treatment. No single measurement technique has yet proven to be universally acceptable, but one approach is the use of rating instruments that summarize the neurological deficit found on clinical examination. Currently, stroke assessment scales may be based on the examination of physical deficits, an inventory of activities of daily living, or a global evaluation of functional outcome. SUMMARY OF REVIEW: Scientific methods for authenticating stroke scales are available in the psychometric and statistical literature. We review currently available stroke scales for their validity and reliability and propose investigations needed to refine further the standardized measurement of neurological deficit following stroke. CONCLUSIONS: We suggest that clinical stroke trials include a physical deficit scale and a global rating during the acute phase and that an activities of daily living scale be added at later points in recovery.
Authors: Katja E Wartenberg; Xia Wang; Paula Muñoz-Venturelli; Alejandro A Rabinstein; Pablo M Lavados; Craig S Anderson; Thompson Robinson Journal: Neurocrit Care Date: 2017-06 Impact factor: 3.210
Authors: Elisabeth A Wilde; Stephen R McCauley; Tara M Kelly; Annie M Weyand; Claudia Pedroza; Harvey S Levin; Guy L Clifton; Kathleen P Schnelle; Monika V Shah; Paolo Moretti Journal: J Neurotrauma Date: 2010-06 Impact factor: 5.269
Authors: Katja E Wartenberg; Sheetal J Sheth; J Michael Schmidt; Jennifer A Frontera; Fred Rincon; Noeleen Ostapkovich; Luis Fernandez; Neeraj Badjatia; E Sander Connolly; Alexander Khandji; Stephan A Mayer Journal: Neurocrit Care Date: 2011-06 Impact factor: 3.210
Authors: David Asuzu; Karin Nyström; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth Journal: Neurocrit Care Date: 2015-10 Impact factor: 3.210
Authors: M Pohl; K Berger; G Ketter; C Krusch; M Pause; W Puschendorf; M Schaupp; J Schleep; M Spranger; D Steube; K Scheidtmann; J Mehrholz Journal: Nervenarzt Date: 2011-06 Impact factor: 1.214
Authors: Michael C Christensen; Stephen Morris; Laura Vallejo-Torres; Catherine Vincent; Stephan A Mayer Journal: Neurocrit Care Date: 2011-10-06 Impact factor: 3.210
Authors: C S Anderson; B V Taylor; G J Hankey; E G Stewart-Wynne; K D Jamrozik Journal: J Neurol Neurosurg Psychiatry Date: 1994-10 Impact factor: 10.154